Patents by Inventor David Scott Wilson
David Scott Wilson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240058453Abstract: Provided herein is a copper-free, non-toxic click hydrogel that exhibits minimal swelling. The hydrogel may be used as a sealant and/or as a delivery vehicle for local administration of substances of interest, such as therapeutic agents.Type: ApplicationFiled: August 3, 2023Publication date: February 22, 2024Inventors: Barbara D. Boyan, Zvi Schwartz, David J. Cohen, Jingyao Deng, David Scott Wilson
-
Patent number: 11801305Abstract: Several embodiments of the present disclosure relate to therapeutic compositions configured to target the liver of a subject and that are useful in the treatment or prevention of one or more of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. In several embodiments, the compositions are configured for clearance of a circulating protein or peptide or antibody associated with one or more of the above-mentioned maladies. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.Type: GrantFiled: December 20, 2019Date of Patent: October 31, 2023Assignee: ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL)Inventors: Jeffrey A. Hubbell, David Scott Wilson
-
Patent number: 11793882Abstract: Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.Type: GrantFiled: December 20, 2019Date of Patent: October 24, 2023Assignee: ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL)Inventors: Jeffrey A Hubbell, David Scott Wilson
-
Patent number: 11707526Abstract: Compositions and methods are described for a polymer hydrogel created by a cycloaddition reaction between an azide and an alkyne that proceeds rapidly without catalyst to produce the polymer hydrogel in less than ninety seconds. The polymer hydrogel can be used in in vivo applications for the localized delivery of therapeutic agent in aqueous solutions. An example of therapeutic delivery of a protein in a mouse model is demonstrated.Type: GrantFiled: January 11, 2022Date of Patent: July 25, 2023Assignees: GEORGIA TECH RESEARCH CORPORATION, CHILDREN'S HEALTHCARE OF ATLANTA, INC.Inventors: Niren Murthy, Christopher Hermann, David Scott Wilson, Xinghai Ning, Barbara D. Boyan, Zvi Schwartz, Robert Guldberg, Tamim Diab
-
Patent number: 11666638Abstract: Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.Type: GrantFiled: December 20, 2019Date of Patent: June 6, 2023Assignees: Ecole Polytechnique Federale de Lausanne (EPFL), Anokion SAInventors: Jeffrey A. Hubbell, Stephane Kontos, Kristen Marie Lorentz, David Scott Wilson, Shuning Gai
-
Patent number: 11654188Abstract: Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.Type: GrantFiled: December 20, 2019Date of Patent: May 23, 2023Assignees: Ecole Polytechnique Federale de Lausanne (EPFL), Anokion, SAInventors: Jeffrey A. Hubbell, David Scott Wilson, Stephane Kontos, Kristen Marie Lorentz, Shuning Gai
-
Publication number: 20230119325Abstract: Several embodiments of the present disclosure relate to therapeutic compositions configured to target the liver of a subject and that are useful in the treatment or prevention of one or more of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. In several embodiments, the compositions are configured for clearance of a circulating protein or peptide or antibody associated with one or more of the above-mentioned maladies. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.Type: ApplicationFiled: July 1, 2022Publication date: April 20, 2023Inventors: Jeffrey A. Hubbell, David Scott Wilson
-
Publication number: 20230115331Abstract: Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.Type: ApplicationFiled: July 1, 2022Publication date: April 13, 2023Inventors: Jeffrey A. Hubbell, David Scott Wilson
-
Publication number: 20230108299Abstract: Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.Type: ApplicationFiled: July 1, 2022Publication date: April 6, 2023Inventors: Jeffrey A. Hubbell, Stephane Kontos, Kristen Marie Lorentz, David Scott Wilson, Shuning Gai
-
Publication number: 20230093483Abstract: Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.Type: ApplicationFiled: July 1, 2022Publication date: March 23, 2023Inventors: Jeffrey A. Hubbell, David Scott Wilson
-
Publication number: 20220370618Abstract: Compositions and methods are described for a polymer hydrogel created by a cycloaddition reaction between an azide and an alkyne that proceeds rapidly without catalyst to produce the polymer hydrogel in less than ninety seconds. The polymer hydrogel can be used in in vivo applications for the localized delivery of therapeutic agent in aqueous solutions. An example of therapeutic delivery of a protein in a mouse model is demonstrated.Type: ApplicationFiled: January 11, 2022Publication date: November 24, 2022Applicants: Georgia Tech Research Corporation, Children's Healthcare of Atlanta, Inc.Inventors: Niren Murthy, Christopher Hermann, David Scott Wilson, Xinghai Ning, Barbara D. Boyan, Zvi Schwartz, Robert Guldberg, Tamim Diab
-
Patent number: 11484599Abstract: Monomers and copolymers are provided that both target antigen presenting cells (APCs) and activate toll-like receptor (TLR) on the APCs. In some embodiments, compositions and methods involve a polymer that targets the mannose receptor on APCs, in addition to activating a TLR. These can then be conjugated to protein antigens to efficiently target antigens to DCs and simultaneously induce the up-regulation of co-stimulatory molecules that are essential for effective T cell activation. This copolymer is a more efficient activator of DCs, as measured by the surface expression of co-stimulatory molecules and the release of proinflammatory cytokines, than the monomeric form the TLR agonist used in the polymer formulation. Aspects of the disclosure relate to novel compounds, methods, and compositions for treating diseases using the compounds, copolymers, and compositions described herein.Type: GrantFiled: September 29, 2016Date of Patent: November 1, 2022Assignee: The University of ChicagoInventors: Jeffrey A. Hubbell, David Scott Wilson, Sachiko Hirosue
-
Publication number: 20220211826Abstract: Several embodiments provided in the present disclosure relate to compositions that carry an antigen to which tolerance is desired, the antigen being coupled, bound, or otherwise joined to a targeting moiety, the targeting moiety configured to direct the composition to the liver of a subject. In several embodiments, the antigen in coupled to the targeting moiety by way of a polymeric linker. In several embodiments, the polymeric linker is configured to liberate the antigen in vivo. Methods of using the compositions to reduce and/or prevent unwanted immune responses against an antigen of interest are also provided.Type: ApplicationFiled: January 3, 2022Publication date: July 7, 2022Inventors: Jeffrey A. Hubbell, David Scott Wilson, Kristen Marie Lorentz, Stephan Kontos
-
Patent number: 11253597Abstract: Compositions and methods are described for a polymer hydrogel created by a cycloaddition reaction between an azide and an alkyne that proceeds rapidly without catalyst to produce the polymer hydrogel in less than ninety seconds. The polymer hydrogel can be used in in vivo applications for the localized delivery of therapeutic agent in aqueous solutions. An example of therapeutic delivery of a protein in a mouse model is demonstrated.Type: GrantFiled: July 3, 2018Date of Patent: February 22, 2022Assignees: Georgia Tech Research Corporation, Children's Healthcare of AtlantaInventors: Niren Murthy, Christopher Hermann, David Scott Wilson, Xinghai Ning, Barbara D. Boyan, Zvi Schwartz, Robert Guldberg, Tamim Diab
-
Patent number: 11253579Abstract: Several embodiments provided in the present disclosure relate to compositions that carry an antigen to which tolerance is desired, the antigen being coupled, bound, or otherwise joined to a targeting moiety, the targeting moiety configured to direct the composition to the liver of a subject. In several embodiments, the antigen in coupled to the targeting moiety by way of a polymeric linker. In several embodiments, the polymeric linker is configured to liberate the antigen in vivo. Methods of using the compositions to reduce and/or prevent unwanted immune responses against an antigen of interest are also provided.Type: GrantFiled: June 14, 2018Date of Patent: February 22, 2022Assignees: The University of Chicago, Anokion SAInventors: Jeffrey A. Hubbell, David Scott Wilson, Kristen Marie Lorentz, Stephan Kontos
-
Publication number: 20210244812Abstract: The present disclosure provides compositions comprising mannose-fused antigens to target mannose receptors. The compositions may be used to prevent immunity or reduce an immune response protein-based drugs that would otherwise elicit an immune response.Type: ApplicationFiled: May 9, 2019Publication date: August 12, 2021Applicants: The University of Chicago, Anokion SAInventors: Jeffrey A. HUBBELL, David Scott WILSON, Kym BRÜNGGEL, Kristen Marie LORENTZ
-
Patent number: 10953101Abstract: Several embodiments of the present disclosure relate to therapeutic compositions configured to target the liver of a subject and that are useful in the treatment or prevention of one or more of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. In several embodiments, the compositions are configured for clearance of a circulating protein or peptide or antibody associated with one or more of the above-mentioned maladies. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.Type: GrantFiled: March 19, 2018Date of Patent: March 23, 2021Assignee: École Polytechnique Fédérale de Lausanne (EPFL)Inventors: Jeffrey A. Hubbell, David Scott Wilson
-
Patent number: 10946079Abstract: Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.Type: GrantFiled: September 19, 2015Date of Patent: March 16, 2021Assignee: ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNEInventors: Jeffrey A. Hubbell, David Scott Wilson
-
Patent number: 10940209Abstract: Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.Type: GrantFiled: July 5, 2018Date of Patent: March 9, 2021Assignee: École Polytechnique Fédérale de Lausanne (EPFL)Inventors: Jeffrey A. Hubbell, David Scott Wilson
-
Patent number: 10821157Abstract: Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.Type: GrantFiled: February 20, 2015Date of Patent: November 3, 2020Assignees: ANOKION SA, ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (“EPFL”)Inventors: Jeffrey A. Hubbell, Stephane Kontos, Kristen Marie Lorentz, David Scott Wilson, Shuning Gai